Amyloid Therapies Show Limited Cognitive Benefit in AD

Alzheimer's disease (AD) is a neurodegenerative condition marked by progressive synaptic dysfunction, neuronal loss, and cognitive decline.^1-3 Existing pharmacological treatments for AD address symptoms but do not stop or reverse the disease's progression.^1-3

AD affects millions globally, with its prevalence projected to rise significantly as the population ages. The disease typically manifests with memory impairment, followed by a decline in other cognitive functions such as language, executive function, and visuospatial skills. The pathological hallmarks of AD include extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. These pathological changes are believed to initiate a cascade of events leading to neuronal damage and cognitive deficits. Current symptomatic treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, offer modest and temporary relief but do not alter the underlying disease trajectory. This unmet medical need underscores the urgency for developing disease-modifying therapies.

Emerging Therapeutic Candidates

Neurosteroids (NSs), endogenous modulators synthesized within the central nervous system (CNS), are being investigated as therapeutic candidates for AD.^1-3 NSs regulate neuronal function, synaptic plasticity, and neurogenesis.^1-3 Specifically, allopregnanolone (AP) and related analogues demonstrate neuroprotective effects by attenuating amyloid-β (Aβ) accumulation, reducing tau hyperphosphorylation, restoring mitochondrial function, and suppressing neuroinflammation.^1-3

NSs modulate intracellular pathways implicated in AD pathogenesis, including mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and brain-derived neurotrophic factor (BDNF).^1-3 They attenuate Aβ- and tau-induced neurotoxicity and neurodegeneration by enhancing neuroprotective autophagy, activating AMPK/BDNF signaling, and suppressing the mTOR signaling pathway.^1-3 However, the precise role of NSs in relation to the mTOR/AMPK/BDNF signaling axis in AD requires further elucidation.^1-3

A review by Khobrani et al. synthesized current knowledge on the molecular mechanisms through which NSs influence the mTORC1/AMPK/BDNF signaling axis, highlighting their therapeutic potential in mitigating AD neuropathology.¹ This review systematically analyzed preclinical studies involving various neurosteroids and their impact on AD-related cellular and molecular pathways. The authors focused on studies employing in vitro models, such as neuronal cell cultures exposed to Aβ or tau aggregates, and in vivo models, primarily transgenic mouse models of AD. The methodology involved a comprehensive literature search across major biomedical databases, followed by a qualitative synthesis of findings related to NS effects on mTOR, AMPK, and BDNF signaling. Understanding the multifaceted actions of NSs may pave the way for novel neuroprotective strategies and future clinical interventions in AD management.¹ Separately, Li et al. investigated alkaloids from Dendrobium Nobile Lindl, finding that they improve mitochondrial function by enhancing the activity of v-ATPase in APP/PS1 mice.² This study utilized a well-established transgenic mouse model of AD (APP/PS1 mice) that overexpresses human amyloid precursor protein (APP) and presenilin 1 (PS1) mutations, leading to accelerated Aβ plaque formation and cognitive deficits. The researchers administered extracts of Dendrobium Nobile Lindl to these mice and assessed mitochondrial function through various biochemical assays, including ATP production, oxygen consumption rates, and v-ATPase activity measurements in brain tissue. Behavioral tests were also conducted to evaluate cognitive improvements. Patel et al. conducted an integrative analysis of pharmacological and non-pharmacological interventions in Alzheimer's dementia, reinforcing the current limitations of existing treatments.³ This analysis involved a broad review of clinical trials and observational studies, categorizing interventions by their primary mechanism of action and evaluating their reported efficacy in improving cognitive and functional outcomes in AD patients. The patient populations in these studies typically included individuals diagnosed with mild to moderate AD, with some studies extending to severe AD. The analysis highlighted the persistent challenges in achieving significant and sustained cognitive benefits with current therapeutic approaches.

Limitations and Future Directions

While the neuroprotective effects of NSs are promising, the exact mechanisms, particularly concerning the mTOR/AMPK/BDNF signaling axis, are not fully understood.¹ Further detailed mechanistic studies are required to delineate the precise molecular targets and downstream effectors of NSs within these pathways. The research on NSs is largely preclinical or review-based, necessitating further clinical trials to confirm efficacy and safety in human populations.^1-3 Future clinical trials should focus on well-defined patient populations, potentially stratifying participants based on AD stage, genetic risk factors, or biomarker profiles to identify those most likely to respond to NS therapy. These trials must also establish optimal dosing regimens, routes of administration, and long-term safety profiles. The current body of evidence suggests a shift in focus from solely amyloid-targeting strategies to broader neuroprotective approaches that address multiple facets of AD pathology, including mitochondrial dysfunction and neuroinflammation.^1-3 This broader perspective acknowledges the complex multifactorial nature of AD and the limitations of single-target therapies. Future research should explore combination therapies that leverage the neuroprotective properties of NSs alongside other disease-modifying agents to achieve more comprehensive therapeutic benefits. Additionally, the development of biomarkers to monitor treatment response and disease progression will be crucial for the successful translation of these promising preclinical findings into effective clinical interventions for AD.